Sun, Jan 25, 2015, 5:50 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

bionerd51 75 posts  |  Last Activity: Jan 20, 2015 9:56 AM Member since: Jan 2, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bionerd51 bionerd51 Dec 2, 2014 9:40 AM Flag

    jrrt1, What's interesting in the SRPT IP strategy is that their position does not make the Kole patent the central issue. The EU Patent Office negated SRPT's patent claim based on the Kole patent which they disregarded due to the fact that it was going to expire

  • bionerd51 bionerd51 Dec 2, 2014 9:12 AM Flag

    jrrt1, One caveat to your interference thoughts is that the USPTO will review ALL the evidence of both parties patents and claims. The Ryszard Kole patent for exon-skipping [inventor] precedes Leiden's. How much weight the USPTO gives the Kole patent will rule the day. The Kole patent expired a couple of years ago. There is also a second consideration that will bear weight in this preceding and that is the USPTO's "new limiting" approach of all broad patent applications and patent decisions [years ago] in an effort to free up innovation.

    Sentiment: Strong Buy

  • Reply to

    Did someone on Wednesday

    by free_will_000 Nov 28, 2014 9:48 AM
    bionerd51 bionerd51 Nov 29, 2014 12:40 PM Flag

    Starfe, What is this "RNA set to close Europe"?? You know that is false so why are you pumping Drisa?? Let me change it around to a more plausible future……Eteplirsen closes down RNA and Drisa. Why, because eteplirsen is safer and more efficacious then Drisa. This takes care of Orphan status [exclusivity] and worse case patent scenario a low single digit royalty pays for use of exon 51. If I was SRPT I wouldn't pay the royalty and set up shop in a non-EU country

    Sentiment: Strong Buy

  • Reply to

    Who is "Arnold"?

    by sswilton Nov 25, 2014 11:25 AM
    bionerd51 bionerd51 Nov 26, 2014 8:54 AM Flag

    Grey, Patents: The basic PMO patents had it's design origins in the late 1970's. Check James Summerton/morpholino patent. The exon-skipping patents that precedes the Dutch's claim inventor: Ryzard Kole.

  • Reply to

    CATCHING RNA'S DRAFT

    by starfe11 Nov 24, 2014 9:45 AM
    bionerd51 bionerd51 Nov 24, 2014 10:04 AM Flag

    Starfe, The Prosensa deal was made because of weakness, not because of strength. 680 mil is pitiful for a platform, if approved, that is worth north of 4 billion. Biomarin ripped them off. It's obvious that BIOmarin received a deep discount because the low probability of FDA approval. The EU is a home rule entity. Also Biomarin is fully cognizant that when eteplirsen is approved their first-to-market " "status" will be shattered when eteplirsen receives approval because eteplirsen meets 2 out of the 2 requirements to breach the Orphan exemption, "safer" OR "more efficacious".

    Sentiment: Strong Buy

  • Reply to

    My take aways on the Iverson talk

    by thigrlsrk Nov 20, 2014 7:28 PM
    bionerd51 bionerd51 Nov 21, 2014 6:22 PM Flag

    A Chief Scientific Officer is the second most important position in a small biotech company. CG couldn't wait to fire PI. He blamed him for slowing down preclinical research and which oligos should enter the clinic. According to CG, Pat couldn't replicate experiments after reporting outstanding results in earlier experimentation. Pat went on a road trip and could not duplicate an antiviral study at a big pharma lab prior to a partnership. Once the exon 51 data came in his first act was to let him go. The company will deny this and say Pat didn't want to move to Mass. but that is BS. Anyone that knows anyone at Corvalis will tell you this. So what does CG do…he hires an RNAi guy who has never work with steric blockers. Brilliant. CG was only interested in the CV of his future CSO, not whether he would be a good fit with SRPT's strength and core platforms.

    Sentiment: Strong Buy

  • Reply to

    My take aways on the Iverson talk

    by thigrlsrk Nov 20, 2014 7:28 PM
    bionerd51 bionerd51 Nov 21, 2014 1:48 PM Flag

    Conrad, Iversen is not coming back. CG had to be begged by antiviral scientists at SRPT to allow Pat consult on ebola. Mickey Mouse would be appointed top scientific officer before PI.

    Sentiment: Strong Buy

  • Reply to

    RNA's bluff

    by immediatereliefxxx Nov 12, 2014 10:02 AM
    bionerd51 bionerd51 Nov 12, 2014 11:04 AM Flag

    Yahoo is slicing and dicing my posts again. Prosensa's own data which illustrates that eteplirsen is 10X's more efficacious and is obviously safer is a dagger in their patent claims and SAREPTA's ability to operate in the EU for exon 51. EU drug agencies allow an exception for the "one drug/first drug" to market rule. It allows a second drug if that drug is safer OR more efficacious then the one approved first. This will have a major impact on SRPT's EU operation.

  • bionerd51 bionerd51 Nov 12, 2014 9:57 AM Flag

    The FDA is not run like the Fiduciary. It has great descretion when determining which drugs should be approved especially Orphan drugs. Read the statutes. In case of a "biomarker" basis for approval, that sounds pretty flexible to me. "Precedent setting", I don't think so.

  • Reply to

    Who Chooses The Members Of Any Adcom Panel?

    by greyzone513 Nov 12, 2014 9:35 AM
    bionerd51 bionerd51 Nov 12, 2014 9:47 AM Flag

    Grey, The FDA commissioner. At present, Hamburg

  • bionerd51 bionerd51 Nov 12, 2014 9:30 AM Flag

    Pasteur, Twisting FDA requirements for AA, again. That is not what the FDA reports when a drug is eligible for AA. A biomarker alone is enough for the FDA to approve under AA as long as the biomarker has a "reasonable" chance to ameliorate stated pathology.

    Sentiment: Strong Buy

  • bionerd51 bionerd51 Nov 12, 2014 8:45 AM Flag

    Grey, I don't think it's "big pharma" or other cos. influencing the FDA. This is a gov't bureaucracy protecting it's turf and power. That's all. The FDA insists that all companies jump through the hoops that they tell them to jump through whether they are arcane or outdated. This reason is worse then "big pharma" scenario.

    Sentiment: Strong Buy

  • bionerd51 bionerd51 Nov 12, 2014 6:12 AM Flag

    Pasteur, Even for you, your response to Christine is about as low as I have ever seen. She is trying to save her son and sons of thousands of parents and you respond that CG only cares about shareholders? I'm not the biggest fan of CG but I know that the families of Duchenne drives him 24/7. Go away.

    Sentiment: Strong Buy

  • Reply to

    Marco passini

    by stox311 Nov 11, 2014 8:15 AM
    bionerd51 bionerd51 Nov 11, 2014 9:01 AM Flag

    Starfe11, Starfe, what happened to you? You use to be a good poster. You're constant bashing of CG and advancing a biotech that failed it's PhaseIII trial and will fail it's proposed subgroup NDA submission because of data, or lack of data.

    Sentiment: Strong Buy

  • bionerd51 by bionerd51 Nov 11, 2014 6:35 AM Flag

    clinical study in EU has commenced. http://www.nasdaq.com/article/sarepta-q3-loss-narrower-than-expected-eteplirsen-in-focus-analyst-blog-cm412148

    Sentiment: Strong Buy

  • Reply to

    Pat Iversen Back in the News...

    by bionerd51 Nov 9, 2014 8:55 PM
    bionerd51 bionerd51 Nov 10, 2014 9:37 AM Flag

    Grey, That is interesting. It must have been tough on CG to approve the consultant job for Iversen, since he let him go right after the initial positive results for eteplirsen. It tells me that Corvalis and Boston needed a PMO reference to call like Pat. Remember Art Krieg was an RNAi guy.

    Sentiment: Strong Buy

  • With press on SRPT's ebola drug. http://www.ktvz.com/news/osu-prof-helps-develop-promising-ebola-drug/29615328

  • Reply to

    simp...(yes, you!)...

    by jrrt1 Nov 8, 2014 2:12 PM
    bionerd51 bionerd51 Nov 8, 2014 3:08 PM Flag

    SRPT's chemistry goes back to the late 1970's. The development of PMO's start there. This precedes the 2'O methyl, prosensa's chemistry. Even though the basic PMO chemistry patent has expired in 2008 they have extended their chemistry patents in multiple ways, one was by connecting them to skipping exonic targets. USTPO will go through the entire history of both chemistries and targets before deciding.

  • Reply to

    simp...(yes, you!)...

    by jrrt1 Nov 8, 2014 2:12 PM
    bionerd51 bionerd51 Nov 8, 2014 2:43 PM Flag

    jrrt1, I have heard that the USPTO's interference decision will come in early 2015 [March]. I am not concerned at all. The US patent office in the last several years has tried to undo the "broadness" to their earlier policy of granting very broad patents. The earlier patent interpretations were stifling innovation in biotech. The have opened it up. Expect a decision that grants Prosensa full patent authority for their compound[s] and stated targets. SRPT will be granted full patent authority for their chemistries and targets. Exons 51, 46 will be either urged to settle or a small royalty will be granted for these 2 targets. If this was the EU Patent Authority all bets would be off because of their history of "home-rulings" in patent disputes.

    Sentiment: Strong Buy

  • Reply to

    PLOS Journal Article..

    by bionerd51 Nov 7, 2014 2:16 PM
    bionerd51 bionerd51 Nov 8, 2014 11:25 AM Flag

    When one carefully follow testing guidelines and good scientific lab technique including strict controls an N=2 is not that big a deal. The data I would like to highlight is on the slide presentation ..intra-assay and inter-assay precision percentages are low single digits using Defiens software

    Sentiment: Strong Buy

TSRX
13.630.0000(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.